Convalescent plasma falls flat in first randomized trial

Plasma from individuals who have recovered from COVID-19 could benefit sick patients, but definitive evidence for or against convalescent plasma is still lacking. A consensus about how it should be deployed is beginning to emerge—and tools and insights to guide its use are becoming available.
Dublin, Ireland

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.